Better Buy: Biogen vs. Cassava Sciences
Alzheimer's disease (AD) causes severe hardships to patients and their families. The disease also comes with a high societal cost of $291 billion per year, according to the U.S. government's Centers For Disease Control and Prevention. Moreover, the number of people with AD -- currently about six million in the U.S. -- is projected to continue growing.
Given these factors, it isn't surprising that several biotechs are working hard at developing medicines for this disease. Two companies that have thrown their hats into this ring are Biogen (NASDAQ: BIIB) and Cassava Sciences (NASDAQ: SAVA).
Other than their interest in AD, these biotechs don't have a whole lot in common. The first is an established drugmaker with a rich lineup that racks up billions in revenue every quarter. The other is a clinical-stage biotech with no products on the market. But could the smaller of these drugmakers, Cassava Sciences, be a better buy at the moment?
Source Fool.com
